Association of single nucleotide polymorphism rs2065955 of the filaggrin gene with susceptibility to Epstein-Barr virus-associated gastric carcinoma and EBV-negative gastric carcinoma

  • Xiaojing Kuang,

    Affiliation Department of Medical Microbiology, Qingdao University Medical College, Qingdao 266021, China

  • Lingling Sun,

    Affiliation Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao 266003, China

  • Shuzhen Liu,

    Affiliation Department of Blood Transfusion, The Affiliated Hospital of Qingdao University, Qingdao 266003, China

  • Zhenzhen Zhao,

    Affiliation Department of Medical Microbiology, Qingdao University Medical College, Qingdao 266021, China

  • Danrui Zhao,

    Affiliation Department of Medical Microbiology, Qingdao University Medical College, Qingdao 266021, China

  • Song Liu,

    Affiliation Department of Medical Microbiology, Qingdao University Medical College, Qingdao 266021, China

  • Bing Luo

    qdluobing@163.com

    Affiliation Department of Medical Microbiology, Qingdao University Medical College, Qingdao 266021, China

    0000-0002-5675-8510

Association of single nucleotide polymorphism rs2065955 of the filaggrin gene with susceptibility to Epstein-Barr virus-associated gastric carcinoma and EBV-negative gastric carcinoma

  • Xiaojing Kuang, 
  • Lingling Sun, 
  • Shuzhen Liu, 
  • Zhenzhen Zhao, 
  • Danrui Zhao, 
  • Song Liu, 
  • Bing Luo
x

Abstract

The relationship between the Filaggrin gene (FLG) rs2065955 polymorphism and susceptibility to Epstein-Barr virus (EBV)-associated gastric carcinoma (EBVaGC) and EBV-negative gastric carcinoma (EBVnGC) was investigated in Shandong Province, China. We detected the FLG rs2065955 genotype and allele distribution by using PCR and restriction fragment length polymorphism (RFLP) in 64 EBVaGC, 82 EBVnGC, and 111 normal control samples. Immunohistochemistry was used to detect the level of FLG protein in 35 EBVaGC and 51 EBVnGC tumor tissues. Compared with normal controls, the genotype CC and allele C of FLG rs2065955 showed higher frequency in EBVaGC and EBVnGC. There was no significant difference between EBVaGC and EBVnGC in allele distribution of FLG rs2065955, but the genotype CC was found more frequently in EBVaGC than in EBVnGC. The risk of developing either EBVaGC or EBVnGC in genotype CC was higher than in other genotypes. Furthermore, genotype CC of FLG rs2065955 may contribute more to the risk of developing EBVaGC than EBVnGC. There was no significant difference in the expression level of FLG protein between EBVaGC and EBVnGC. In conclusion, the FLG rs2065955 polymorphism was significantly related to gastric carcinoma. Allele C of FLG rs2065955 could be a risk factor for EBVaGC or EBVnGC, while genotype CC of FLG rs2065955 was especially associated with EBVaGC.

INTRODUCTION

Epstein-Barr virus (EBV), a well-known tumor-causing virus, is closely associated with several human lymphoid and epithelial tumors, such as Burkitt's lymphoma, Hodgkin's disease, AIDS-associated lymphoma, nasopha-ryngeal carcinoma, and gastric cancer (Thompson et al., 2004). In the last 20 years, the relationship between EBV infection and the occurrence of gastric carcinoma has been confirmed. EBV infection is found in 80%-100% of gastric lymphoepithelioma-like carcinoma cases and 2%-16% of ordinary gastric adenocarcinoma cases (Fukayama et al., 1994; Wu et al., 2000; Andal et al., 2003; Lee et al., 2004; ). The worldwide occurrence of EBV-associated gastric carcinoma (EBVaGC) is esti-mated at more than 50, 000 cases per year (Takada, 2000). Therefore, it is also widely accepted that EBVaGC is one of the most common cancers among EBV-related malignancies.

The development of gastric cancer is a complex, multi-step process involving multiple genetic and epigenetic alterations in oncogenes, tumor suppressor genes, DNA repair genes, cell cycle regulators, and signaling mo-lecules (Nagini, 2012). Recognition of bacteria or viruses by the diversification level of the cytokine response and immune system is closely related to polymorphisms in host inflammatory response genes (Garza-gonzalez et al., 2005). Analysis of polymorphisms in genes related to the inflammatory response in the gastric mucosa and the associated risk for malignancy has been the central focus of many studies (Rad et al., 2009; Partida-rodriguez et al., 2010). However, little is known about the association of host gene polymorphisms with EBVaGC develop-ment.

Filaggrin (FLG) is an intermediate-filament-associated protein that aggregates keratin intermediate filaments in the epidermis. It plays an important role in the function of skin as a barrier against invasion of harmful factors from the external environmental, including micro-organisms (Candi et al., 2005). Mutations in the FLG gene are associated with some skin disorders such as atopic dermatitis (Palmer et al., 2006) and ichthyosis vulgaris (Smith et al., 2006). A recent study found that loss-of-function mutations of FLG were closely associated with higher incidence of human papillomavirus (HPV)-related cancers and pre-cancers (Skaaby et al., 2014).

In a previous study, we used a high-throughput sequencing method (RNA-Seq) to compare the transcript-omes of the gastric cancer cell lines AGS and AGS-EBV to determine the impact of EBV on gastric cancer and uncover clues to the tumorigenic mechanisms of EBV. The RNA-Seq results showed 929 single nucleotide polymorphisms (SNPs) between the two cell lines (Supplementary Table S1). There were 539 SNPs in intronic regions and 162 in exonic regions. Among those SNPs in exonic regions, 110 were synonymous mutations while 72 were nonsynonymous mutations. Of the 72 nonsy nonymous mutations, 25 SNPs were associated with tumors, and FLG rs2065955 was among them (Table 1). As considerable interest has arisen in the possible relationship between EBVaGC development and FLG gene polymorphisms, we looked for the FLG rs2065955 polymorphism in EBVaGC and EBV-negative gastric carcinoma (EBVnGC) tissues and tried to provide experimental evidence for genetic susceptibility to development of gastric carcinoma, especially EBVaGC.

thumbnail
Table 1. SNPs associate with tumors

MATERIALS AND METHODS

Specimens

One hundred and forty-six paraffin-embedded gastric carcinoma tissues, including 64 EBVaGC and 82 EBVnGC, were collected from the Department of Pathology of the Affiliated Hospital of Qingdao University, which is located in Shandong Province, northern China (Table 2; please check Supplementary Table S2 for more details). EBV-positive samples were determined by in situ hybridization for EBV-encoded small RNA 1 as described previously (Khan et al., 1992). One hundred and one healthy physical examinees from the Affiliated Hospital of Qingdao University were used as normal controls; 5 mL of fasting venous blood was collected using EDTA as an anticoagulant, and peripheral blood mononuclear cells were separated for DNA extraction. This study was approved by the Medical Ethics Committee of Qingdao University Medical College, and informed consent was obtained from all the study participants.

thumbnail
Table 2. Clinical characterizations of EBVaGC/EBVnGC patients and healthy controls

DNA extraction

DNA of venous blood specimens was extracted by a standard method using proteinase K digestion and phe-nol-chloroform purification. A QIAamp DNA FFPE tissue kit (QIAGEN GmbH, Hilden, Germany) was used to extract the DNA from paraffin-embedded gastric carcinoma tissues.

FLG gene polymorphism detection

PCR and restriction fragment length polymorphism (RFLP) were used to detect FLG rs2065955 located in the 25265th nucleotide of the FLG gene. Nucleotide substitution of G to C leads to an amino acid change from Gly to Ala in this mutation. Primers Forward (5′-CCAGACACTCAGGCATTC-3′) and Reverse (5′-CAATCGGTAGAATAGGTGG-3′) produced a PCR product of 436 bp.

PCR reactions were performed with 2 μL of DNA extracts (100 ng/μL) in a 25 μL reaction mixture containing standard PCR buffer, 1.5 mmol/L MgCl2, 200 μmol/L dNTPs, 1.25 μmol/L of each primer, and 0.2 U Taq DNA polymerase (TaKaRa Biotechnology Co, Kyoto, Japan). Cycle conditions were pre-denaturation at 94 ℃ for 5 min, then 40 cycles of 94 ℃ for 30 s, 60 ℃ for 30 s, and 72 ℃ for 1 min, and final elongation at 72 ℃ for 10 min. The PCR products were separated on a 1.5% agarose gel. After electrophoresis, the gels were stained with ethidium bromide and photographed under a UV light transilluminator. Sterile double-distilled water was used as a negative control in each PCR reaction. PCR products were purified using a gel extraction kit (Qiaex Ⅱ; Qiagen) according to the manufacturer's instructions. Restriction enzymatic reactions were performed in a 25 μL mixture including 2.5 μL 10× buffer, 0.5 μL 10 U/μL ApaLI, 5 μL PCR product, and 17 μL enzyme-free double-distilled water. After incubation at 37 ℃ for 15 min, the DNA products were analyzed on a 2% agarose gel and then visualized by ethidium bromide staining.

FLG protein expression detection

Formalin-fixed, paraffin-embedded tissue slides (4 μm thick) were deparaffinized and rehydrated, and subjected to antigen retrieval, followed by blocking of endogenous peroxidase and treatment with a blocking reagent for nonspecific binding. Slides were then incubated over-night with the primary antibody, a rabbit polyclonal antibody against human FLG (1:500; ab24584; Abcam) at 4 ℃ in a humidified chamber. PBS was used as a negative control replacing the primary antibody.

All immunohistochemistry evaluation was performed in a blinded manner by an attending pathologist. Specimens were graded by staining intensity (0: negative; 1: weak; 2: moderate; 3: strong) and the percentage of tumor cells (0: 0%-5%; 1: 6%-25%; 2: 26%-75%; 3: 76%-100%). The final score was calculated by multiplying these two variables. A score of 1-2 indicated weakly positive (1+), a score of 3-4 indicated moderately posi-tive (2+) and a score > 4 indicated intensely positive (3+).

Statistical analysis

The Chi-square test and Fisher's exact test were used to compare the differences in genotype and allele frequencies of FLG rs2065955 in each group. Nonconditional logistic regression was used to estimate the odds ratio (OR) and P values to indicate the correlation between genotype and the risk of gastric carcinoma. Results were considered to be statistically significant when P < 0.05. Statistical analyses were conducted using SPSS 19.0 sta-tistical software (SPSS, Chicago, IL).

RESULTS

The 436 bp fragments of the FLG gene flanking the rs2065955 locus were successfully amplified in 64 EBVaGC, 82 EBVnGC, and 111 normal control samples (Figure 1). After digestion by ApaLI, the homozygous wild-type genotype GG remained as only one 436 bp band. The homozygous mutant genotype CC showed two bands, 368bp and 68bp. The heterozygous genotype GC showed three bands, 368 bp, 68 bp, and 436 bp (Figure 2).

thumbnail
Fig 1. Electrophoresis results of FLG gene (rs2065955) PCR products. Lane M: DL 2000 DNA Marker; lane 16: negative control; lanes 1-15: 436 bp FLG (rs2065955) PCR products.

thumbnail
Fig 2. PCR-RFLP analysis of FLG gene (rs2065955) genotyping. Lane M: DL 2000 DNA Marker; lanes 1, 4, 7, 12, 15: GG genotype (homozygous wild-type); lanes 5, 6, 8, 9, 13, 14: GC genotype (heterozygous type); lanes 2, 3, 10, 11: CC genotype (homozygous mutated type).

The distributions of FLG rs2065955 genotypes and alleles in EBVaGC, EBVnGC, and normal controls are shown in Table 3 and Table 4. The CC genotype was found in 38 of 64(59.4%) EBVaGC samples, 31 of 82(37.8%) EBVnGC samples, and 17 of 111(15.3%) normal controls. The distribution of the CC genotype was signifi-cantly different among the three groups (EBVaGC vs normal control: χ2 = 36.566, P < 0.01; EBVnGC vs normal control: χ2 = 12.766, P < 0.01; EBVaGC vs EBVnGC: χ2 = 6.701, P = 0.01). The CC genotype showed higher frequency in EBVaGC and EBVnGC than in normal controls and may be a risk factor for EBVaGC and EBVnGC (EBVaGC vs normal control: OR = 8.081, 95% CI = 3.941-16.571; EBVnGC vs normal control: OR = 3.361, 95% CI = 1.698-6.652; EBVaGC vs EBVnGC: OR = 2.404, 95% CI = 1.231-4.496).

thumbnail
Table 3. Genotype and allele frequencies of FLG (rs2065955) in EBVaGCs and EBVnGCs

thumbnail
Table 4. Distribution of genotype and allele of FLG in EBVaGC, EBVnGC, and control samples

Allele C frequency was 70.3%, 61%, and 48.2% in EBVaGC, EBVnGC, and normal controls, respectively. Allele C exhibited higher frequency in EBVaGC and EBVnGC than in normal controls and may be a risk factor for EBVaGC and EBVnGC (EBVaGC vs normal control: χ2 = 16.137, P < 0.01, OR = 2.687, 95% CI = 1.683-4.289; EBVnGC vs normal control: χ2 = 6.192, P = 0.013, OR = 1.679, 95% CI = 1.698-6.652; EBVaGC vs EBVnGC: P = 0.097).

FLG protein expression level in 35 EBVaGC and 51 EBVnGC tissue samples was detected by immunochemical methods (Table 5, Figure 3). The scoring criteria are mentioned in the MATERIALS AND METHODS section. The statistical analysis using Fisher's exact test showed that there was no significant difference in FLG protein expression level between EBVaGC and EBVnGC (P = 0.079).

thumbnail
Table 5. FLG protein expression level in EBVnGC and EBVaGC tissues

thumbnail
Fig 3. Immunohistochemical analysis of FLG. (A) FLG negative expression in tumor cells. (B) weakly positive (1+). (C) moderately positive (2+). The arrow indicates the specific cytoplasmic expression of FLG in gastric tumor cells. (Magnification: 100 ×)

DISCUSSION

In this study, we found that genotype CC of FLG showed higher frequency in gastric carcinoma, especially in EBVaGC, which may be a risk factor for EBVaGC development. To our knowledge, this is the first research describing the association of FLG polymorphism with EBV-associated diseases.

Filaggrin proteins are crucial for the terminal differentiation of the epidermis by aggregating keratin filaments. They play important roles in the barrier function of skin, which may prevent the entry of harmful factors from environmental exposure including microorganisms, allergens, or chemicals (Candi et al., 2005). Loss-of-function mutations in the FLG gene reduce epidermal filaggrin levels and may disrupt the skin barrier, and have been shown to be highly associated with ichthyosis vulgaris (Smith et al., 2006) and atopic dermatitis (Palmer et al., 2006). In addition to the skin, filaggrin proteins are also expressed in the oral cavity, cervix, endometrium, and vagina (De benedetto et al., 2008; Irvine et al., 2011). FLG loss-of-function mutations also confer a higher risk of rhinitis, asthma, and food allergies in the context of atopic dermatitis (De benedetto et al., 2008). However, the role of filaggrin outside the skin is largely unknown.

A few studies have reported the association of FLG mutations with the pathogenesis of certain carcinomas (Chen et al., 2013; Skaaby et al., 2014; Bager et al., 2015). Filaggrin expression was reported to be reduced in cervical lesions infected with HPV in a dose-depen-dent manner (Cintorino et al., 1988; Mcglennen et al., 1991; Lara et al., 1994). One report declared that FLG mutations were not associated with the risk of cervical cancer (Bager et al., 2015). However, Skaaby (2014) reported that FLG mutations led to greater susceptibility to infection by HPV and thus may confer a higher risk of HPV-related cancer and pre-cancer.

We detected FLG rs2065955 in EBVaGC, EBVnGC, and normal controls. The association of this SNP with disease has not been reported previously. The distribution of the FLG gene SNP (rs2065955) was significantly different between the three groups. A higher proportion of genotype CC in gastric carcinoma (EBVaGC and EBVnGC) suggested that this genotype may be a risk factor for development of gastric carcinoma. A higher frequency of genotype CC in EBVaGC than in EBVnGC indicated that genotype CC may be associated with susceptibility to EBV infection and may contribute to the pathogenesis of EBVaGC. Despite significant diffe-rences in FLG rs2065955 polymorphism between EBVaGC and EBVnGC samples, there was no significant difference in FLG protein level between the two groups. To date, however, there have been no reports of EBV infection associated with FLG gene expression levels. A nucleotide mutation at one site only may affect the amino acid sequence of the encoded protein, but it does not necessarily cause changes in expression level. However, further work is needed to confirm this phenomenon. First, we have to confirm the expression of FLG in mucosa of the nose, oral cavity (the natural entrance of EBV to invade the human body), and stomach, which is the basis of the pathogenic role of FLG mutations. Second, a much larger-scale study of gastric carcinomas from different geographical regions should be undertaken to eliminate the possibility of sampling errors. Third, samples from other EBV-associated diseases such as nasopharyngeal carcinoma also should be included. In conclusion, our study found an interesting phenomenon in EBVaGC, which provides a new clue to tumorigenicity of EBV.

ACKNOWLEDGMENTS

This study was funded by the National Natural Science Foundation of China (NSFC 81571995), Specialized Research Fund for the Doctoral Program of Higher Education, (20133706110001), and the Natural Science Founda-tion of Shandong Province (ZR2015HM069).

COMPLIANCE WITH ETHICS GUIDELINES

The authors declare that there is no conflict of interest. Additional informed consent was obtained from all patients for whom identifying information is included in this article.

AUTHOR CONTRIBUTIONS

BL and XK designed the experiments. XK, ZZZ, and DZ carried out the experiments. LS, SL, ZZZ, DZ, and SL analyzed the data. LS, XK, and BL wrote the paper. All authors have read and approved the final manuscript.

Supplementary tables are available on the websites of Virologica Sinica: www.virosin.org; link.springer.com/journal/12250

SUPPLEMENTARY MATERIAL

Table S1. RNA-Seq results showed 929 SNPs between the gastric cancer cell lines AGS and AGS-EBV

Table S2. Detail information for EBVaGC/EBVnGC patients and healthy controls

References

  1. . Andal N, Shanthi P, Krishnan KB, Taralaxmi V. 2003. The epstein barr virus and gastric carcinoma. Indian J Pathol Microbiol, 46: 34-36.
  2. . Artero-Castro A, Castellvi J, García A, Hernández J, Ramón y Cajal S, Lleonart ME. 2011. Expression of the ribosomal proteins Rplp0, Rplp1, and Rplp2 in gynecologic tumors. Hum Pathol, 42: 194-203.
  3. . Ashkenazi S, Ortenberg R, Besser M, Schachter J, Markel G. 2016. SOX9 indirectly regulates CEACAM1 expression and immune resistance in melanoma cells. Oncotarget.
  4. . Bager P, Wohlfahrt J, Sørensen E, Ullum H, Høgdall C K, Palle C, Husemoen LL, Linneberg A, Kjaer SK, Melbye M, Thyssen JP. 2015. Common filaggrin gene mutations and risk of cervical cancer. Acta Oncol, 54: 217-223.
  5. . Bowers AJ, Boylan JF. 2004. Nek8, a NIMA family kinase member, is overexpressed in primary human breast tumors. Gene, 328: 135-142.
  6. . Candi E, Schmidt R, Melino G. 2005. The cornified envelope: A model of cell death in the skin. Nat Rev Mol Cell Biol, 6: 328-340.
  7. . Chang EY, Chang YC, Shun CT, Tien YW, Tsai SH, Hee SW, Chen IJ, Chuang LM. 2016. Inhibition of Prostaglandin Reductase 2, a Putative Oncogene Overexpressed in Human Pancreatic Adenocarcinoma, Induces Oxidative Stress-Mediated Cell Death Involving xCT and CTH Gene Expressions through 15-Keto-PGE2. PLoS One, 11: e0147390.
  8. . Chang H, Jeung HC, Jung JJ, Kim TS, Rha SY, Chung HC. 2011. Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells. Breast Cancer Res Treat, 125: 55-63.
  9. . Chen H, Ma J, Sunkel B, Luo A, Ding F, Li Y, He H, Zhang S, Xu C, Jin Q, Wang Q, Liu Z. 2013. S100a14: Novel modulator of terminal differentiation in esophageal cancer. Mol Cancer Res, 11: 1542-1553.
  10. . Cintorino M, Syrjanen S, Leoncini P, Bellizzi De Marco E, Petracca R, Pallini V, Tosi P, Mantyjarvi R, Syrjanen K. 1988. Altered expression of filaggrin in human papillomavirus (HPV) lesions of the uterine cervix. Arch Gynecol Obstet, 241: 235-247.
  11. . Cooper CD, Liggins AP, Ait-Tahar K, Roncador G, Banham AH, Pulford K. 2006. PASD1, a DLBCL-associated cancer testis antigen and candidate for lymphoma immunotherapy. Leukemia, 20: 2172-2174.
  12. . De Benedetto A, Qualia CM, Baroody FM, Beck LA. 2008. Filaggrin expression in oral, nasal, and esophageal mucosa. J Invest Dermatol, 128: 1594-1597.
  13. . Fleming JM, Ginsburg E, Oliver SD, Goldsmith P, Vonderhaar BK. 2012. Hornerin, an S100 family protein, is functional in breast cells and aberrantly expressed in breast cancer. BMC Cancer, 12: 266.
  14. . Fukayama M, Hayashi Y, Iwasaki Y, Chong J, Ooba T, Takizawa T, Koike M, Mizutani S, Miyaki M, Hirai K. 1994. Epstein-barr virus-associated gastric carcinoma and epstein-barr virus infection of the stomach. Lab Invest, 71: 73-81.
  15. . Garza-Gonzalez E, Bosques-Padilla FJ, El-Omar E, Hold G, Tijerina-Menchaca R, Maldonado-Garza HJ, Perez-Perez GI. 2005. Role of the polymorphic il-1b, il-1rn and tnf-a genes in distal gastric cancer in mexico. Int J Cancer, 114: 237-241.
  16. . Irvine AD, McLean WH, Leung DY. 2011. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med, 365: 1315-1327.
  17. . Khan G, Coates PJ, Gupta RK, Kangro HO, Slavin G. 1992. Presence of epstein-barr virus in hodgkin's disease is not exclu-sive to reed-sternberg cells. Am J Pathol, 140: 757-762.
  18. . Kim Y1, Choi JW, Lee JH, Kim YS. 2014. Loss of CDC14B expression in clear cell renal cell carcinoma: meta-analysis of microarray data sets. Am J Clin Pathol, 141: 551-558.
  19. . Lara C, Serra V, Marzo C, Valcuende F, Castells A, Bonilla-Musoles F M. 1994. Immunohistochemical localization of filaggrin in benign, premalignant and malignant cervical tissue. Arch Gynecol Obstet, 255: 73-79.
  20. . Lee MA, Hong YS, Kang JH, Lee KS, You JY, Lee KY, Park CH. 2004. Detection of epstein-barr virus by pcr and expression of lmp1, p53, cd44 in gastric cancer. Korean J Intern Med, 19: 43-47.
  21. . Lian YF, Yuan J, Cui Q, Feng QS, Xu M, Bei JX, Zeng YX, Feng L. 2016. Upregulation of KLHDC4 predicts a poor prognosis in human nasopharyngeal carcinoma. PLoS One, 11: e0152820.
  22. . Ling XH, Chen ZY, Luo HW, Liu ZZ, Liang YK, Chen GX, Jiang FN, Zhong WD. 2016. BCL9, a coactivator for Wnt/β-catenin transcription, is targeted by miR-30c and is associated with prostate cancer progression. Oncol Lett. Mar, 11: 2001-2008.
  23. . McGlennen RC, Ostrow RS, Carson LF, Stanley MS, Faras AJ. 1991. Expression of cytokine receptors and markers of differentiation in human papillomavirus-infected cervical tissues. Am J Obstet Gynecol, 165: 696-705.
  24. . Nagini S. 2012. Carcinoma of the stomach: A review of epide-miology, pathogenesis, molecular genetics and chemoprevention. World J Gastrointest Oncol, 4: 156-169.
  25. . Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee S P, Goudie DR, Sandilands A, Campbell LE, Smith FJ, O'Regan GM, Watson RM, Cecil JE, Bale SJ, Compton JG, DiGiovanna JJ, Fleckman P, Lewis-Jones S, Arseculeratne G, Sergeant A, Munro CS, El Houate B, McElreavey K, Halkjaer LB, Bisgaard H, Mukhopadhyay S, McLean WH. 2006. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet, 38: 441-446.
  26. . Partida-Rodriguez O, Torres J, Flores-Luna L, Camorlinga M, Nieves-Ramirez M, Lazcano E, Perez-Rodriguez M. 2010. Polymorphisms in tnf and hsp-70 show a significant association with gastric cancer and duodenal ulcer. Int J Cancer, 126: 1861-1868.
  27. . Rad R, Ballhorn W, Voland P, Eisenacher K, Mages J, Rad L, Ferstl R, Lang R, Wagner H, Schmid RM, Bauer S, Prinz C, Kirschning CJ, Krug A. 2009. Extracellular and intracel-lular pattern recognition receptors cooperate in the recognition of helicobacter pylori. Gastroenterology, 136: 2247-2257.
  28. . Rak R, Haklai R, Elad-Tzfadia G, Wolfson HJ, Carmeli S, Kloog Y. 2014. Novel LIMK2 Inhibitor Blocks Panc-1 Tumor Growth in a mouse xenograft model. Oncoscience, 1: 39-48.
  29. . Rangel MM, Chaible LM, Nagamine MK, Mennecier G, Cogliati B, de Oliveira KD, Fukumasu H, Sinhorini IL, Mir LM, Dagli ML. 2015. Electroporation transiently decreases GJB2 (connexin 26) expression in B16/BL6 melanoma cell line. J Membr Biol, 248: 47-52.
  30. . Roh SA, Park IJ, Yoon YS, Kwon YH, Chung JH, Kim TW, Cho DH, Lim BH, Kim SK, Kim SY, Kim YS, Kim JC. 2016. Feasibility of novel PPP1R15A and proposed ANXA11 single nucleotide polymorphisms as predictive markers for bevacizumab regimen in metastatic colorectal cancer. J Cancer Res Clin Oncol, 142: 1705-1714.
  31. . Skaaby T, Husemoen LL, Jorgensen T, Johansen JD, Menne T, Szecsi PB, Stender S, Bager P, Thyssen JP, Linneberg A. 2014. Associations of filaggrin gene loss-of-function variants and human papillomavirus-related cancer and pre-cancer in da-nish adults. PLoS One, 9: e99437.
  32. . Smith FJ, Irvine AD, Terron-Kwiatkowski A, Sandilands A, Campbell LE, Zhao Y, Liao H, Evans AT, Goudie DR, Lewis-Jones S, Arseculeratne G, Munro CS, Sergeant A, O'Regan G, Bale S J, Compton JG, DiGiovanna JJ, Presland RB, Fleckman P, McLean WH. 2006. Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. Nat Genet, 38: 337-342.
  33. . Takada K. 2000. Epstein-barr virus and gastric carcinoma. Mol Pathol, 53: 255-261.
  34. . Thompson MP, Kurzrock R. 2004. Epstein-barr virus and cancer. Clin Cancer Res, 10: 803-821.
  35. . Venturutti L, Cordo Russo RI, Rivas MA, Mercogliano MF, Izzo F, Oakley RH, Pereyra MG, De Martino M, Proietti CJ, Yankilevich P, Roa JC, Guzmán P, Cortese E, Allemand DH, Huang TH, Charreau EH, Cidlowski JA, Schillaci R, Elizalde PV. 2016. MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1. Oncogene.
  36. . Wang J, Ying Y, Bo S, Li G, Yuan F. 2016. Differentially expressed microRNA-218 modulates the viability of renal cell carcinoma by regulating BCL9. Mol Med Rep, 14: 1829-1834.
  37. . Wu J, Lei H, Zhang J, Chen X, Tang C, Wang W, Xu H, Xiao W, Gu W, Wu Y. 2016. Momordin Ic, a new natural SENP1 inhi-bitor, inhibits prostate cancer cell proliferation. Oncotarget: 10636.
  38. . Wu MS, Shun CT, Wu CC, Hsu TY, Lin MT, Chang MC, Wang HP, Lin JT. 2000. Epstein-barr virus-associated gastric carcinomas: Relation to h. Pylori infection and genetic alterations.. Gastroenterology, 118: 1031-1038.
  39. . Wu Y, Peng Y, Wu M, Zhang W, Zhang M, Xie R, Zhang P, Bai Y, Zhao J, Li A, Nan Q, Chen Y, Ren Y, Liu S, Wang J. 2016. Oncogene FOXK1 enhances invasion of colorectal carcinoma by inducing epithelial-mesenchymal transition. Oncotarget.
  40. . Xie M, Sun M, Zhu YN, Xia R, Liu YW, Ding J, Ma HW, He XZ, Zhang ZH, Liu ZJ, Liu XH, De W. 2015. Long noncoding RNA HOXA-AS2 promotes gastric cancer proliferation by epigene-tically silencing P21/PLK3/DDIT3 expression. Oncotarget, 6: 33587-33601.
  41. . Xu X, Xu L, Gao F, Wang J, Ye J, Zhou M, Zhu Y, Tao L. 2014. Identification of a novel gene fusion (BMX-ARHGAP) in gastric cardia adenocarcinoma. Diagn Pathol, 9: 218.
  42. . Zang WQ, Yang X, Wang T, Wang YY, Du YW, Chen XN, Li M, Zhao GQ. 2015. MiR-451 inhibits proliferation of esophageal carcinoma cell line EC9706 by targeting CDKN2D and MAP3K1. World J Gastroenterol, 21: 5867-5876.
  43. . Zhang W, Liu H, Liu Z, Zhu D, Amos CI, Fang S, Lee JE, Wei Q. 2015. Functional Variants in Notch Pathway Genes NCOR2, NCSTN, and MAML2 Predict Survival of Patients with Cutaneous Melanoma. Cancer Epidemiol Biomarkers Prev., 24: 1101-1110.
  44. . Zhang Y, Tian Y, Yu JJ, He J, Luo J, Zhang S, Tang CE, Tao YM. 2013. Overexpression of WDR62 is associated with centrosome amplification in human ovarian cancer. J Ovarian Res, 6: 55.
  45. . Zhao D, Liu S, Sun L, Zhao Z, Liu S, Kuang X, Shu J, Luo B. 2016. Glypican-4 gene polymorphism (rs1048369) and suscep-tibility to Epstein-Barr virus-associated and -negative gastric carcinoma. Virus Res, 220: 52-56.
  46. . Zhao N, Yang K, Yang G, Chen D, Tang H, Zhao D, Zhao C. 2013. Aberrant expression of clock gene period1 and its correlations with the growth, proliferation and metastasis of buccal squamous cell carcinoma. PLoS One, 8: e55894.
  47. . Zheng L, Sun D, Fan W, Zhang Z, Li Q, Jiang T. 2015. Diagnostic value of SFRP1 as a favorable predictive and prognostic biomarker in patients with prostate cancer. PLoS One, 10: e0118276.